Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes.
Ulcerative colitis
endoscopy
quality of life
Journal
Current medical research and opinion
ISSN: 1473-4877
Titre abrégé: Curr Med Res Opin
Pays: England
ID NLM: 0351014
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
pubmed:
25
5
2022
medline:
25
8
2022
entrez:
24
5
2022
Statut:
ppublish
Résumé
This systematic literature review (SLR) assessed the effects of endoscopic mucosal healing and histologic remission on clinical, quality-of-life (QoL), and economic outcomes in adults with ulcerative colitis (UC) in the real-world setting. Literature searches of Embase and MEDLINE (6 July 2020) and conference proceedings (2017-2020) were performed according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Eligible studies included adults with UC with documented endoscopic mucosal healing or histologic remission. Clinical, QoL, and economic outcomes were extracted and narratively synthesized. Of 1603 studies screened, 25 met eligibility criteria and collectively included 2813 patients (mean age: 34-60 years). The most commonly reported indices were Mayo endoscopic score (MES) for endoscopic mucosal healing ( This SLR demonstrated consistent evidence of improved clinical outcomes among UC patients with endoscopic mucosal healing and histologic remission. Ulcerative colitis (UC) is a chronic, relapsing disease characterized by inflammation of the mucous membranes lining the rectum and colon. While medical management has traditionally focused on lessening UC symptoms, there is growing recognition that the reduction of underlying inflammation visible endoscopically (called endoscopic mucosal healing) or microscopically (called histologic remission) can be an objective indicator of disease improvement. This research is the first systematic literature review to assess the effects of endoscopic mucosal healing and histologic remission on clinical, quality-of-life (QoL), and economic outcomes in adults with UC in the real-world setting. We included studies in adults with UC who had mucosal healing or histologic remission and analyzed clinical, QoL, and economic outcomes using a technique called narrative synthesis. Twenty-five of 1603 studies screened met our eligibility criteria for inclusion in the analysis. In most studies, over 50% of patients with endoscopic mucosal healing did not relapse during follow-up, with better relapse-free survival rates reported among patients with a Mayo endoscopic scores of 0 than among those with a score of 1. Likewise, patients with histologic remission had higher relapse-free survival rates than those without histologic remission. Rates of clinical remission, steroid-free remission, hospitalization, and colectomy avoidance were better among patients with mucosal healing and/or histologic remission. Two studies also reported better QoL outcomes. Our findings suggest that endoscopic mucosal healing or histologic remission is associated with improved clinical and QoL outcomes. While more information is required, these measures should be considered important when making therapeutic decisions for patients with UC.
Autres résumés
Type: plain-language-summary
(eng)
Ulcerative colitis (UC) is a chronic, relapsing disease characterized by inflammation of the mucous membranes lining the rectum and colon. While medical management has traditionally focused on lessening UC symptoms, there is growing recognition that the reduction of underlying inflammation visible endoscopically (called endoscopic mucosal healing) or microscopically (called histologic remission) can be an objective indicator of disease improvement. This research is the first systematic literature review to assess the effects of endoscopic mucosal healing and histologic remission on clinical, quality-of-life (QoL), and economic outcomes in adults with UC in the real-world setting. We included studies in adults with UC who had mucosal healing or histologic remission and analyzed clinical, QoL, and economic outcomes using a technique called narrative synthesis. Twenty-five of 1603 studies screened met our eligibility criteria for inclusion in the analysis. In most studies, over 50% of patients with endoscopic mucosal healing did not relapse during follow-up, with better relapse-free survival rates reported among patients with a Mayo endoscopic scores of 0 than among those with a score of 1. Likewise, patients with histologic remission had higher relapse-free survival rates than those without histologic remission. Rates of clinical remission, steroid-free remission, hospitalization, and colectomy avoidance were better among patients with mucosal healing and/or histologic remission. Two studies also reported better QoL outcomes. Our findings suggest that endoscopic mucosal healing or histologic remission is associated with improved clinical and QoL outcomes. While more information is required, these measures should be considered important when making therapeutic decisions for patients with UC.
Identifiants
pubmed: 35608153
doi: 10.1080/03007995.2022.2081453
doi:
Types de publication
Journal Article
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM